Edwards Lifesciences (EW) PT Raised to $125 at Jefferies

Jefferies analyst Raj Denhoy reiterated a Buy rating and raised his price target on Edwards Lifesciences (NYSE: EW) to $125.00 (from $105.00) following strong results and outlook.

Denhoy commented, "EW delivered another exceptionally strong quarter. US TAVR sales were up a remarkable 64%—and this was before the expansion into the intermediate-risk population. Guidance is going higher, partially on lower FX and partially on better underlying performance. EW remains a top pick."

The firm raised Q2 EPS from $0.64 to $0.69, FY 2016 EPS from $2.68 to $2.73 and FY 2017 EPS from $3.11 to $3.27.

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $108.84 yesterday.

You May Also Be Interested In

• JPMorgan Downgrades KOSE Corporation (4922:JP) (KSRYY) to Underweight
• Freedom Broker Starts HF Sinclair (DINO) at Hold
• ServiceTitan (TTAN) PT Raised to $103 at BMO Capital on 'Strong Bounce Back'